Parkinson'
Conditions
Interventions
2 tablets of dispersible form of levodopa which contains 100 mg of levodopa and 25 mg of benserazide,37 grams of Mucuna pruriens powder which contains 1,000 mg of levodopa
Dispersible form of levodopa,Mucuna pruriens powder
Sponsors
National Research Council of Thailand (NRCT)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1)PD patients above 18 years of age (2)Patients who diagnose PD according to UKPDSBB criteria. (3)Patients whose symptoms were stable and medication dosage remained same within 3 months. (4)Patients who had motor complication at least 2 hours per day in awakening time. (5)Patients who had ability to record PD diary.
Exclusion criteria
Exclusion criteria: (1)Patients who had H&Y stage 5 in off period. (2)Patients who had uncontrolled psychotic symptoms . (3)Patients who had dementia determine by TMSE score < 23. (4)Patients who pregnant (5)Patients who currently use drugs that interfere gastric emptying times (6)Patients who had unstable disease such as heart disease or renal failure (7)Patients who had diabetes (8)Patients who allergy to leguminous plant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic 6 hours period AUC, Tmax, Cmax | — |
Secondary
| Measure | Time frame |
|---|---|
| UPDRS score 6 hours period UPDRS part 3 | — |
Countries
Thailand
Contacts
Public ContactThanatat Boonmongkol
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed